Popular on eTradeWire
- Stephanie Peppers Launches Rethread Chronicles - 165
- Real Estate Investor Shane Seo Hosts Empowering Workshop in Atlanta for Aspiring Investors - 149
- Celebrate National Direct Support Recognition Week, September 8 – 14, 2024 - 135
- Cozy Up with Adirondack Fragrance Farm's New Soy Wax Melts - 108
- History Matters: Book Recommendations for September 2024 - 104
- Allegiant Management Group Launches New Website Following Recent Rebranding
- Wagoner Roofing Launches New Website
- Atlas Elite Entertainment Releases New Single "Forever"
- 20th Annual Family Pumpkin Patch Day
- Colony Ridge Welcomes A Second DG Market!
Similar on eTradeWire
- New Short-Term Care Insurance Has Some Attractive Features
- Hypothesis by Richard H. Davis: Carrier Pigeons and Milk Immunity
- Tutanota LLC Extends Tender Offer for up to 350,000 Shares of Common Stock of Alphabet Inc
- IVF Lab 2.0: The Ultimate Guide to Launching Your Cutting-Edge Clinic
- New Frontier Aerospace Closes Seed Round with Pacific Bays Capital
- UCLA Researchers Develop High-Sensitivity Paper-based Sensor for Rapid Cardiac Diagnostics
- Auxo Medical Introduces Imaging Equipment Field Service Throughout the Mid-Atlantic Region
- Global Coalition to Shine Light on Life-Altering Disease Affecting Lives Worldwide
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- The Crucial Role of Cryopreservation in IVF Success
AI Team from "PersonalAIze" Expert Assessment; Groundbreaking AI Platform Starting with Early Cancer Detection: Renovaro; Stock Symbol: RENB
eTradeWire News/10781794
PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform.
AMSTERDAM - eTradeWire -- Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Independent Expert Assessment Validates RENB RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from "PersonalAIze" Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which the RENB RenovaroCube is based.
More on eTradeWire News
The RENB RenovaroCube AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.
The initial aim for RENB is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.
Based on these findings, PersonalAIze is eager to collaborate further with RENB RenovaroCube to enhance and commercialize the platform.
This partnership for RENB could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.
RENB RenovaroCube Presented Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
RENB has presented two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.
One RENB presentation describes the development of a deep learning model that leverages cell-free DNA (cfDNA) fragmentation features (fragmentomics) from a small sample of blood to detect cancer. The results show that in comparison to state-of-the-art cfDNA cancer detection models, we were able to perform on par while utilizing only minute amounts of genetic data. The integration of fragmentomics into the Cube's current platform, further enhances its capacity to detect cancer, potentially leading to earlier and/or better treatment options and improved patient outcomes.
More on eTradeWire News
A second RENB study demonstrated the Cube platform's ability to correlate methylation patterns from cancer tissue in cfDNA derived from plasma, indicating that cancer can be detected in blood samples as an alternative for invasive tissue biopsies.
To Review $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc.
Contact Person: The Hon. Mark Dybul, MD, CEO
Company Websites: www.renovarobio.com
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Independent Expert Assessment Validates RENB RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from "PersonalAIze" Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which the RENB RenovaroCube is based.
More on eTradeWire News
- A Celebration of American Music Benefit at North Coast Repertory Theatre
- The Human Resilience Project Launches Groundbreaking Global Study on Human Resilience
- Dark Truth Behind Targeted Mass Violence
- Energy Psychology Group Announces Conclusion of Strategic Alliance with Cosmic Media
- Los Defensores Launches "Siempre Contigo" Community Initiative with Philanthropic Grants to Mark the Expansion of Its Local Houston Initiatives
The RENB RenovaroCube AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.
The initial aim for RENB is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.
Based on these findings, PersonalAIze is eager to collaborate further with RENB RenovaroCube to enhance and commercialize the platform.
This partnership for RENB could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.
RENB RenovaroCube Presented Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
RENB has presented two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.
One RENB presentation describes the development of a deep learning model that leverages cell-free DNA (cfDNA) fragmentation features (fragmentomics) from a small sample of blood to detect cancer. The results show that in comparison to state-of-the-art cfDNA cancer detection models, we were able to perform on par while utilizing only minute amounts of genetic data. The integration of fragmentomics into the Cube's current platform, further enhances its capacity to detect cancer, potentially leading to earlier and/or better treatment options and improved patient outcomes.
More on eTradeWire News
- Jazz Artist Bob Holz Signs With SoVibe Entertainment Plus Album Review In September 2024 Issue Of Downbeat Magazine
- CacklePatch, LLC Unveils The Legend of CacklePatch – The Halloween Raccoon
- Prize Draw UK hosts first successful live draw on Facebook
- 2024 Mount Dora Mayoral Forum Candidates Answer the Burning Questions
- 4-Star Gold Coast Hotel Showcases Chicago Artist's Watercolors
A second RENB study demonstrated the Cube platform's ability to correlate methylation patterns from cancer tissue in cfDNA derived from plasma, indicating that cancer can be detected in blood samples as an alternative for invasive tissue biopsies.
To Review $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc.
Contact Person: The Hon. Mark Dybul, MD, CEO
Company Websites: www.renovarobio.com
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on eTradeWire News
- AXELERA Technologies Prepares for AUSA Annual meeting, Showcasing the 3d_4X Joystick
- The New Real Estate "Just Looking" Program Is A Big Hit With Central Florida Residents!
- Introducing DentalDuo: The Ultimate On-the-Go Oral Care Tool Now Available
- Pineberry Manufacturing Inc. to Exhibit Automation Solutions at PACK EXPO International
- New High-Performance System for AI and Edge-Computing Applications
- The Florida Forum Speaker Series to Welcome Rt Hon Boris Johnson
- SCSA Announces 2024 Recipients of the Jeff Henson Memorial Scholarship
- CostPredict Inc. Accepted for Participation in an Exclusive Tech Venture Accelerator Program
- Are California Insurance Tax Hikes Good for Uninsurable Homes?
- New California Solar Incentives and Tax Credits
- Ohio Central donates diesel locomotive #4092 to the Age of Steam Roundhouse Museum
- Human Factors and Ergonomics Society Announces 2024 Stanley Caplan User-Centered Product DesignAward
- The Pink Locket to Showcase 'Escape to the Caribbean' Collection at Rock & Roll Hall of Fame
- Plastic Fabrication Company Shares Benefits of Medical Device Plastics
- Mobile windshield service provides welcome post-storm relief
- Cell-Ed and National Minority Health Association Forge Strategic Partnership to Expand Caregiving and Health Equity Initiatives
- 8 Liner Machines deliver an entertainment experience upgrade
- NEXT Door & Window Named Among Crain's 2024 Best Places to Work in Chicago
- Unveiling the attaché x: a premium business bag where luxury meets innovation with a £1 launch offer
- Delta Industrial is Attending FabTech 2024 in Orlando This Fall